drugset / Trial / NCT00905333
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Phase 1
Completed
36 enrolled
AstraZeneca
Cori Analyticals · collabFaculty of Pharmaceutical Sciences of Ribeirão Preto - Bioequivalence Center · collabHospital Sirio-Libanes · collabLabClin Laboratório Clínico · collabLaboratório de Patologia Clínica Dr. Franceschi Ltda. · collabScentryphar Clinical Research · collab
CrossoverOpen-label
Summary
The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®
Timeline
- Start
- 2008-10
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candesartan | Unknown | 16 mg | Oral |
| Subject | Candesartan cilexetil | Unknown | 16 mg | Oral |
| Subject | Felodipine | Small molecule | 5 mg | Oral |
Indications
No indication recorded.